Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapies aimed at preventing breast cancer recurrences. The company's mission is to address the significant unmet medical need for patients who have previously undergone surgery for breast cancer. Headquartered in Stafford, Texas, a suburb of Houston, the company was incorporated in Delaware in 2006.

The company's primary product candidate is GP2, an immunotherapy also referred to as GLSI-100 when combined with GM-CSF. This treatment targets HER2/neu-positive breast cancer patients, focusing on preventing the recurrence of the disease after initial surgery. GP2 is a 9 amino acid transmembrane peptide derived from the HER2/neu protein, which is expressed in a significant percentage of breast cancers.

Greenwich LifeSciences is currently advancing GLSI-100 through its global Phase III clinical trial, known as FLAMINGO-01. Recent developments include the presentation of FLAMINGO-01 Phase III trial open-label data at the ASCO Meeting 2026 and European regulatory approval for the use of commercially manufactured GP2 in the FLAMINGO-01 trial. The company received FDA Fast Track designation in September 2025. Snehal S. Patel serves as the Chief Executive Officer. The company aims to build on promising Phase IIb results, which indicated an 80% or greater reduction in metastatic breast cancer recurrence rates over five years.